stat-2

Security and immunogenicity of Fc-EDA, a recombinant ectodysplasin A1 alternative protein, in human topics.

 

In X-linked hypohidrotic ectodermal dysplasia (XLHED), essentially the most frequent ectodermal dysplasia, an inherited deficiency of the signaling protein ectodysplasin A1 (EDA1) impairs the improvement of the pores and skin and its appendages, numerous eccrine glands, and dentition.

The extreme hypohidrosis frequent to XLHED sufferers could result in life-threatening hyperthermia, particularly throughout scorching climate or febrile sickness. Fc-EDA, an EDA1 alternative protein recognized to forestall the illness in new child animals, was examined in two scientific trials (human adults and neonates) and moreover administered beneath compassionate use to 3 infants in utero. The information help the protection of Fc-EDA and efficacy if utilized prenatally.

Anti-drug antibodies have been detected after intravenous administration in grownup males and non-pregnant females, however not in pregnant girls when Fc-EDA was delivered intra-amniotically. Most significantly, there was no detectable immune response to the investigational drug in neonates handled by intravenous infusions and in infants who had acquired Fc-EDA in utero. In conclusion, the protection profile of this drug encourages additional improvement of prenatal EDA1 alternative remedy.

 

 

Recombinant Human CD40 Ligand/CD40L/TNFSF5

 

Description: Lyophilized from a 0.2 μm filtered resolution of 20mM PB, 200mM NaCl, 0.1mM EDTA, pH 7.0.

 

The efficacy and security of recombinant human soluble thrombomodulin (rhsTM) haven’t been positively confirmed. The consequences could depend upon the presence of sepsis-associated coagulopathy (SAC).

stat-2

stat-2

 

The purpose of this systematic evaluation and meta-analysis was to guage the efficacy and security of rhsTM in sufferers with SAC outlined by excessive worldwide normalized ratio and low platelet depend.EMBASE, MEDLINE, CENTRAL and clinicaltrial.gov have been looked for randomized managed trials (RCTs) evaluating rhsTM with placebo or no remedy in sufferers with sepsis.

The efficacy end result was 28-day mortality, and the protection end result was main bleeding. We included three RCTs with a complete of 1,633 sufferers. 28-day mortality was greater in sufferers with SAC in contrast with these with out SAC (threat ratio [RR] 1.32; 95% confidence intervals [CI], 1.06-1.64).

rhsTM was related to considerably decrease 28-day mortality in contrast with placebo or no remedy in sufferers with SAC (RR 0.80; 95% CI, 0.65-0.98), however not in these with out SAC (RR 1.17; 95% CI, 0.82-1.67) nor in the entire examine inhabitants (RR 0.88; 95% CI, 0.74-1.04).

There was no vital distinction in main bleeding between rhsTM and controls in the entire inhabitants (RR 1.25; 95% CI, 0.80-1.96), sufferers with SAC (RR 0.94; 95% CI, 0.45-1.95), and people with out SAC (RR 2.26; 95% CI, 0.95-5.35).In sufferers with sepsis, SAC is related to greater 28-day mortality.

The administration of rhsTM diminished 28-day mortality in sufferers with SAC, however not in these with out SAC.

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, Untagged, E.coli-100ug

 

In evaluating new medicine for the remedy of assorted kinds of most cancers, investigations have been made to find a wide range of anti-tumor compounds with much less unwanted effects on regular cells.

Investigations have proven that the heterodimers S100A8 and S100A9 inhibit the enzyme casein kinase 2 after which prevents the activation of the E7 oncoprotein. Subsequently, the purpose of this examine was to guage the impact of calprotectinas antitumor compound on the Nalm6 (B cell precursor leukemia cell line). Transformation of genes encoding S100Aeight and S100A9 human, designed within the pQE32 plasmid, was carried out by thermal shock technique into E. coli M15 micro organism.

After bacterial progress in LB medium, the expression of two S100A8 and S100A9 subunits the solubility of the protein by SDS-PAGE technique was decided. Lastly, the S100A8 / A9 complicated was equally positioned within the microtube.

Within the subsequent step, the cytotoxic results of calprotectin produced on the Nalm6 cell line have been evaluated utilizing the wst1 check. Then, the apoptosis in these cells was measured utilizing stream cytometry strategies with Annexin-V coloration.

Within the present examine the outcomes confirmed that cytotoxic results of Calprotectin is time and focus dependent. So, it could actually cut back the tumor expression and had helpful impact by induced apoptosis in Nalm6 cell line.Calprotectin has anti-tumor impact on Nalm6 cell line by rising apoptosis.

 

 

CD154/CD40L/TNFSF5

E21-I56 10ug
EUR 343

Polyclonal Goat anti-GST α-form

GST-ANTI-1 50 uL
EUR 280

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 280

Recombinant Human CD40 Ligand/CD40L/TNFSF5

CI56-10ug 10ug
EUR 146
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 200mM NaCl, 0.1mM EDTA, pH 7.0.

Recombinant Human CD40 Ligand/CD40L/TNFSF5

CI56-1mg 1mg
EUR 2283
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 200mM NaCl, 0.1mM EDTA, pH 7.0.

Recombinant Human CD40 Ligand/CD40L/TNFSF5

CI56-500ug 500ug
EUR 1613
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 200mM NaCl, 0.1mM EDTA, pH 7.0.

Recombinant Human CD40 Ligand/CD40L/TNFSF5

CI56-50ug 50ug
EUR 303
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 200mM NaCl, 0.1mM EDTA, pH 7.0.

Human CellExp? CD40 Ligand / TNFSF5, Human Recombinant

P1174-10
EUR 164

Human CellExp? CD40 Ligand / TNFSF5, Human Recombinant

P1174-50
EUR 555

CD40LG/TNFSF5 (Cd40 Ligand) Antibody

20-abx111483
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul
  • Shipped within 5-10 working days.

Recombinant Human CD40 Ligand/CD40L/TNFSF5 (E. coli)

C011-10ug 10ug
EUR 100
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 200mM NaCl, 0.1mM EDTA, pH 7.0.

Recombinant Human CD40 Ligand/CD40L/TNFSF5 (E. coli)

C011-1mg 1mg
EUR 943
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 200mM NaCl, 0.1mM EDTA, pH 7.0.

Recombinant Human CD40 Ligand/CD40L/TNFSF5 (E. coli)

C011-500ug 500ug
EUR 674
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 200mM NaCl, 0.1mM EDTA, pH 7.0.

Recombinant Human CD40 Ligand/CD40L/TNFSF5 (E. coli)

C011-50ug 50ug
EUR 192
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 200mM NaCl, 0.1mM EDTA, pH 7.0.

Human CellExp? CD40 Ligand / TNFSF5, Fc tag, Human Recombinant

P1175-10
EUR 164

Human CellExp? CD40 Ligand / TNFSF5, Fc tag, Human Recombinant

P1175-50
EUR 555

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, Untagged, E.coli-100ug

QP10359-ec-100ug 100ug
EUR 525

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, Untagged, E.coli-10ug

QP10359-ec-10ug 10ug
EUR 154

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, Untagged, E.coli-250ug

QP10359-ec-250ug 250ug
EUR 898

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, Untagged, E.coli-50ug

QP10359-ec-50ug 50ug
EUR 290

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, Untagged, E.coli-1mg

QP5332-1mg 1mg
EUR 1361

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, Untagged, E.coli-500ug

QP5332-500ug 500ug
EUR 826

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, GST, E.coli-100ug

QP8528-ec-100ug 100ug
EUR 408

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, GST, E.coli-10ug

QP8528-ec-10ug 10ug
EUR 200

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, GST, E.coli-1mg

QP8528-ec-1mg 1mg
EUR 1632

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, GST, E.coli-200ug

QP8528-ec-200ug 200ug
EUR 634

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, GST, E.coli-500ug

QP8528-ec-500ug 500ug
EUR 1060

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, GST, E.coli-50ug

QP8528-ec-50ug 50ug
EUR 263

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, His, Yeast-100ug

QP9047-ye-100ug 100ug
EUR 480

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, His, Yeast-10ug

QP9047-ye-10ug 10ug
EUR 236

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, His, Yeast-1mg

QP9047-ye-1mg 1mg
EUR 1885

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, His, Yeast-200ug

QP9047-ye-200ug 200ug
EUR 744

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, His, Yeast-500ug

QP9047-ye-500ug 500ug
EUR 1206

Recombinant Human CD40L/ CD154/ TNFSF5 Protein, His, Yeast-50ug

QP9047-ye-50ug 50ug
EUR 299

 

Human Monokine Induced By Interferon Gamma (MIg) ELISA Equipment

 

Automated patch clamp (APC) devices allow environment friendly analysis of electrophysiologic results of medicine on human cardiac currents in heterologous expression methods.

Variations in experimental protocols, devices, and dissimilar web site procedures have an effect on the variability of IC50 values characterizing drug block efficiency. This impacts the utility of APC platforms for assessing a drug’s cardiac security margin.

We decided variability of APC knowledge from a number of websites that measured blocking efficiency of 12 blinded medicine (with totally different ranges of proarrhythmic threat) towards 4 human cardiac currents (hERG [IKr], hCav1.2 [L-Type ICa], peak hNav1.5, [Peak INa], late hNav1.5 [Late INa]) with really useful protocols (to reduce variance) utilizing 5 APC platforms throughout 17 websites. IC50 variability (25/75 percentiles) differed for medicine and currents (e.g., 10.4-fold for dofetilide block of hERG present and 4-fold for mexiletine block of hNav1.5 present).

Inside-platform variance predominated for Four of 12 hERG blocking medicine and Four of 6 hNav1.5 blocking medicine. hERG and hNav1.5 block. Bland-Altman plots depicted various settlement throughout APC platforms.

A follow-up survey recommended a number of sources of experimental variability that may very well be additional minimized by stricter adherence to plain protocols. Adoption of greatest practices would guarantee much less variable APC datasets and improved security margins and proarrhythmic threat assessments.

Human Monokine Induced By Interferon Gamma (MIg) ELISA Kit

RD-MIg-Hu-48Tests 48 Tests
EUR 318

Human Monokine Induced By Interferon Gamma (MIg) ELISA Kit

RD-MIg-Hu-96Tests 96 Tests
EUR 432

Human Monokine Induced By Interferon Gamma (MIg) ELISA Kit

RDR-MIg-Hu-48Tests 48 Tests
EUR 331

Human Monokine Induced By Interferon Gamma (MIg) ELISA Kit

RDR-MIg-Hu-96Tests 96 Tests
EUR 451

anti- MIG antibody

FNab05188 100µg
EUR 505.25
  • Recommended dilution: WB: 1:500-1:2000
  • Immunogen: chemokine(C-X-C motif) ligand 9
  • Uniprot ID: Q07325
  • Gene ID: 4283
  • Research Area: Immunology, Signal Transduction
Description: Antibody raised against MIG

Anti-MIG antibody

PAab05188 100 ug
EUR 355

Anti-MIG antibody

STJ98702 200 µl
EUR 197
Description: Rabbit polyclonal to MIG.

Anti-MIG (1F5)

YF-MA14255 100 ug
EUR 363
Description: Mouse monoclonal to MIG

Mouse Monokine Induced By Interferon Gamma (MIg) ELISA Kit

DLR-MIg-Mu-48T 48T
EUR 454
  • Should the Mouse Monokine Induced By Interferon Gamma (MIg) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Monokine Induced By Interferon Gamma (MIg) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Mouse Monokine Induced By Interferon Gamma (MIg) ELISA Kit

DLR-MIg-Mu-96T 96T
EUR 587
  • Should the Mouse Monokine Induced By Interferon Gamma (MIg) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Monokine Induced By Interferon Gamma (MIg) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Rat Monokine Induced By Interferon Gamma (MIg) ELISA Kit

DLR-MIg-Ra-48T 48T
EUR 475
  • Should the Rat Monokine Induced By Interferon Gamma (MIg) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Monokine Induced By Interferon Gamma (MIg) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Rat Monokine Induced By Interferon Gamma (MIg) ELISA Kit

DLR-MIg-Ra-96T 96T
EUR 616
  • Should the Rat Monokine Induced By Interferon Gamma (MIg) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Monokine Induced By Interferon Gamma (MIg) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Mouse Monokine Induced By Interferon Gamma (MIg) ELISA Kit

RD-MIg-Mu-48Tests 48 Tests
EUR 450

Mouse Monokine Induced By Interferon Gamma (MIg) ELISA Kit

RD-MIg-Mu-96Tests 96 Tests
EUR 622

Rat Monokine Induced By Interferon Gamma (MIg) ELISA Kit

RD-MIg-Ra-48Tests 48 Tests
EUR 473

Rat Monokine Induced By Interferon Gamma (MIg) ELISA Kit

RD-MIg-Ra-96Tests 96 Tests
EUR 655

Mouse Monokine Induced By Interferon Gamma (MIg) ELISA Kit

RDR-MIg-Mu-48Tests 48 Tests
EUR 470

Mouse Monokine Induced By Interferon Gamma (MIg) ELISA Kit

RDR-MIg-Mu-96Tests 96 Tests
EUR 651

Rat Monokine Induced By Interferon Gamma (MIg) ELISA Kit

RDR-MIg-Ra-48Tests 48 Tests
EUR 495

Rat Monokine Induced By Interferon Gamma (MIg) ELISA Kit

RDR-MIg-Ra-96Tests 96 Tests
EUR 685

Rabbit Polyclonal antibody Anti-CRBN

Anti-CRBN 50 µg
EUR 349

Anti-MIG/CXCL9 Antibody

PB9694 100ug/vial
EUR 294

Anti-MIG/CXCL9 Antibody

PA1429 100ug/vial
EUR 334

anti-Mig-6 (clone 4)

AR18-MA0001 100 ul
EUR 334
Description: Mouse monoclonal to Mig-6

MIG/CXCL9, Human

HY-P7253 10ug
EUR 268

MIG, human recombinant

4240-1000
EUR 4563

MIG, human recombinant

4240-20
EUR 289

MIG, CXCL9, human

RC312-20 5ug
EUR 104.38
  • Product category: Proteins/Recombinant Proteins/Cytokines

Armenian Hamster Anti-Mouse CXCL9 (MIG) Monoclonal antibody, clone MIG-2F5.5

CABT-L4535-1mg 1 mg
EUR 897

Armenian Hamster Anti-Mouse CXCL9 (MIG) Monoclonal antibody, clone MIG-2F5.5

CABT-L4535-5mg 5 mg
EUR 2405

rHu MIG

AK9979-0005 5µg Ask for price

rHu MIG

AK9979-0020 20µg Ask for price

rHu MIG

AK9979-0100 100µg Ask for price

rHu MIG

AK9979-1000 1mg Ask for price

MIG antibody

70R-MR007 50 ug
EUR 327
Description: Affinity purified Rabbit polyclonal MIG antibody

MIG antibody

10R-M169A 500 ug
EUR 273
Description: Mouse monoclonal MIG antibody

MIG protein

30R-2543 20 ug
EUR 358
Description: Purified recombinant Human MIG protein

MIG protein

30R-2544 20 ug
EUR 358
Description: Purified recombinant Mouse MIG protein

MIG protein

30R-AM013 20 ug
EUR 273
Description: Purified recombinant Human MIG protein

Mouse Anti-Insulin IgG ELISA Kit, 96 tests, Quantitative

3700-MIG 1 Kit
EUR 773

Recombinant Human MIG (CXCL9)

7-02002 5µg Ask for price

Recombinant Human MIG (CXCL9)

7-02003 20µg Ask for price

Recombinant Human MIG (CXCL9)

7-02004 1mg Ask for price

MIG/CXCL9/ Rat MIG/ CXCL9 ELISA Kit

ELA-E1928r 96 Tests
EUR 886

Polyclonal Goat anti-GST α-form

GST-ANTI-1 50 uL
EUR 280

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 280

MIG Polyclonal Antibody

ES8639-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against MIG from Human. This antibody is tested and validated for IHC, WB, ELISA

MIG Polyclonal Antibody

ES8639-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against MIG from Human. This antibody is tested and validated for IHC, WB, ELISA

MIG Polyclonal Antibody

ABP59277-003ml 0.03ml
EUR 158
  • Immunogen information: Synthesized peptide derived from part region of human MIG protein at amino acid sequence of 90-125
  • Applications tips:
Description: A polyclonal antibody for detection of MIG from Human. This MIG antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human MIG protein at amino acid sequence of 90-125

MIG Polyclonal Antibody

ABP59277-01ml 0.1ml
EUR 289
  • Immunogen information: Synthesized peptide derived from part region of human MIG protein at amino acid sequence of 90-125
  • Applications tips:
Description: A polyclonal antibody for detection of MIG from Human. This MIG antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human MIG protein at amino acid sequence of 90-125